These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Ongoing 2005-000403-33 Randomized clinical trial to evaluate the predictive accuracy of a gene expression profile-based test to select patients for preoperative taxane/anthracycline chemotherapy for stage I-III breast cance... not-yet-due
Ongoing 2005-000405-56 RANDOMIZED CLINICAL TRIAL TO COMPARE THE BENEFIT OF ADDING HERCEPTIN TO CAPECITABINE PLUS VINORELBINE AS SECOND LINE TREATMENT FOR PATIENTS WITH LOCALLY ADVANCED NON OPERABLE OR METASTATIC BREAST CAN... not-yet-due
Ongoing 2005-001117-17 PHASE IV.II, CLINICAL TRIAL, WITH THE COMBINATION OF PEGYLATED LIPOSOMAL DOXORUBICIN (CAELYX), CYCLOPHOSPHAMIDE AND TRASTUZUMAB (HERCEPTIN) IN PATIENTS WITH METASTATIC BREAST CANCER WITH OVEREXPRESSIO... not-yet-due
Completed, but no date 2005-005734-12 ENSAYO CLÍNICO FASE IV.II, MULTICÉNTRICO, PARA LA ADMINISTRACIÓN DE CAPECITABINA SIMULTÁNEA A RADIOTERAPIA EN PACIENTES CON RECICIVA LOCAL DE CÁNCER DE MAMA Y TUMORES HER2 NEGATIVOS bad-data
Ongoing 2006-004510-41 ESTUDIO MULTICÉNTRICO FASE II DE DISTRIBUCIÓN ALEATORIA, PARA EVALUAR LA EFICACIA DE TRATAMIENTO NEOADYUVANTE SELECTIVO SEGÚN SUBTIPO INMUNOHISTOQUÍMICO EN CÁNCER DE MAMA HER2 NEGATIVO not-yet-due
Not reported 2007-002841-19 "Estudio aleatorizado, multicéntrico para evaluar la eficacia y seguridad de bevacizumab en combinación con letrozol comparado con letrozol solo, en mujeres postmenopáusicas con cáncer de mama localme... 2013-08-26 due-trials
Completed, but no date 2007-003417-14 Ensayo fase III aleatorizado, multicéntrico, abierto, de grupos paralelos para comparar la eficacia y tolerabilidad de Fulvestrant (Faslodex®) durante tres años en combinación con Anastrozol (Arimidex... bad-data
Ongoing 2007-007031-13 ESTUDIO MULTICÉNTRICO FASE II DE DISTRIBUCIÓN ALEATORIA, PARA COMPARAR EL TRATAMIENTO DE EPIRUBICINA Y CICLOFOSFAMIDA SEGUIDO DE DOCETAXEL Y TRASTUZUMAB VERSUS EPIRUBICINA Y CICLOFOSFAMIDA SEGUIDO DE ... not-yet-due
Ongoing 2010-022689-29 Ensayo prospectivo, abierto, no comparativo para determinar la incidencia de náuseas y vómitos inducidos por la quimioterapia (NVIQT) asociada al régimen docetaxel-ciclofosfamida en pacientes con cánc... not-yet-due
Ongoing 2011-004476-10 Phase II, open-label, non-randomized study of nab-paclitaxel for the neoadjuvant treatment of patients with stage II and III luminal breast cancer. not-yet-due
Ongoing 2012-000174-37 A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recur... not-yet-due
Ongoing 2012-004928-38 A phase III clinical trial to evaluate patient´s preference of subcutaneous trastuzumab (SC) versus intravenous (IV) administration in patients with HER2 positive Advanced Breast Cancer (ABC) who hav... not-yet-due
Ongoing 2013-003170-27 Phase III study of Palbociclib (PD-0332991) in combination with Endocrine therapy (exemestano or fulvestrant) versus chemotherapy (capecitabine) in Hormonal Receptor (HR) positive/HER2 negative Metast... not-yet-due
Ongoing 2015-002437-21 A randomized, double-blind, parallel-group, multicentre, phase II study to compare the efficacy and tolerability of fulvestrant (FaslodexTM) 500mg with placebo and fulvestrant (FaslodexTM) 500mg in co... not-yet-due
Ongoing 2016-001407-23 A Phase II Clinical Trial to analyse Olaparib Response in patients with BRCA1 and/or 2 Promoter Methylation Diagnosed of Advanced Breast Cancer (COMETA-Breast study). not-yet-due
Ongoing 2016-001779-54 A multicenter phase II trial to evaluate the efficacy and safety of pembrolizumab and gemcitabine in patients with HER2-negative Advanced Breast Cancer (ABC). “PANGEA-Breast” not-yet-due
Ongoing 2017-002850-35 “LONG-TERM FOLLOW-UP STUDY OF EARLY STAGE BREAST CANCER PATIENTS INCLUDED IN GEICAM STUDIES”. not-yet-due